$BYLT
Elite Performance Holding Corp

2024 Q3 Form 10-Q Financial Statement

#000147793224004946 Filed on August 15, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $611.00
YoY Change -100.0% -96.36%
Cost Of Revenue $0.00 $5.560K
YoY Change -100.0% -62.81%
Gross Profit $0.00 -$4.949K
YoY Change -100.0% -367.66%
Gross Profit Margin -809.98%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $275.0K $182.1K
YoY Change -25.64% -46.34%
Operating Profit -$275.0K -$187.0K
YoY Change -25.6% -44.58%
Interest Expense $86.07K $47.89K
YoY Change 110.98% 34.38%
% of Operating Profit
Other Income/Expense, Net -$83.37K -$47.89K
YoY Change 172.38% 34.38%
Pretax Income
YoY Change
Income Tax
% Of Pretax Income
Net Earnings -$358.3K -$235.0K
YoY Change -10.46% -37.01%
Net Earnings / Revenue -38463.5%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 109.0M shares 106.4M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $94.00 $22.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory $25.76K $25.76K
Prepaid Expenses $22.27K $14.07K
Receivables
Other Receivables
Total Short-Term Assets $48.12K $39.85K
YoY Change -66.38% -82.0%
LONG-TERM ASSETS
Property, Plant & Equipment $30.26K $33.00K
YoY Change -26.66% -25.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $114.2K $122.8K
YoY Change -25.65% -24.34%
TOTAL ASSETS
Total Short-Term Assets $48.12K $39.85K
Total Long-Term Assets $114.2K $122.8K
Total Assets $162.3K $162.6K
YoY Change -45.3% -57.61%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $944.6K $897.9K
YoY Change 9.89% 24.63%
Accrued Expenses $290.8K $253.1K
YoY Change -20.55% -26.45%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $3.345M $3.006M
YoY Change 19.16% 16.96%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $3.345M $3.006M
Total Long-Term Liabilities
Total Liabilities $3.502M $3.168M
YoY Change 17.15% 15.11%
SHAREHOLDERS EQUITY
Retained Earnings -$9.880M -$9.522M
YoY Change 16.52% 17.85%
Common Stock $12.76K $12.68K
YoY Change -1.89% -1.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$3.340M -$3.005M
YoY Change
Total Liabilities & Shareholders Equity $162.3K $162.6K
YoY Change -45.3% -57.61%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$358.3K -$235.0K
YoY Change -10.46% -37.01%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
35000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000000 shares
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
465000000 shares
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements include the operations of the Company and its wholly-owned subsidiary, Elite Beverage International Corp.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All significant intercompany accounts and transactions have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s consolidated financial statements are prepared using the accrual method of accounting and are presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The Company has elected a calendar year-end.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2024Q2 us-gaap Inventory Net
InventoryNet
25761 usd
CY2024Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
14069 usd
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
0 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
897945 usd
CY2024Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
697153 usd
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
633314 usd
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
253076 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
397112 usd
CY2024Q2 elite Advance From Customer
AdvanceFromCustomer
12000 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1124489 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
820250 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3005685 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2964683 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
66673 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
76930 usd
CY2023Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
95485 usd
CY2024Q2 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
162158 usd
CY2023Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
172415 usd
CY2024Q2 us-gaap Liabilities
Liabilities
3167843 usd
CY2023Q4 us-gaap Liabilities
Liabilities
3137098 usd
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
1000 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
1000 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
12683 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
13040 usd
CY2024Q2 elite Shares To Be Issued
SharesToBeIssued
50000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-9521819 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-8790188 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3005198 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2966360 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
162645 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
170738 usd
CY2020Q2 us-gaap Shortterm Debt Average Outstanding Amount
ShorttermDebtAverageOutstandingAmount
201352 usd
us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
239 usd
CY2023Q1 us-gaap Interest Income Expense After Provision For Loan Loss
InterestIncomeExpenseAfterProvisionForLoanLoss
239 usd
us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
90000 usd
CY2023Q1 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
50000 usd
CY2023 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
75000 usd
CY2022 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
20000 usd
CY2021 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
2000 usd
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
205000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
20000 usd
CY2023Q4 elite Balances Of Advances
BalancesOfAdvances
215000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10000 usd
dei Entity Central Index Key
EntityCentralIndexKey
0001753681
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
35000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000000 shares
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
10000000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
465000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
130397550 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109001270 shares
CY2023Q1 elite Shares Issued In Connection With Convertible Debt Shares
SharesIssuedInConnectionWithConvertibleDebtShares
0 shares
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
0 usd
CY2023Q2 elite Shares To Be Issued For Services Amount
SharesToBeIssuedForServicesAmount
0 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
0 shares
CY2023 elite Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedNumber
0 shares
CY2023 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0 shares
elite Share Based Compensation Arrangement By Share Based Payment Award Options Expired Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredNumber
0 shares
CY2023 elite Share Based Compensation Arrangement By Share Based Payment Award Options Expired Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredNumber
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
0 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0
CY2024Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
0 usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-55987
dei Entity Registrant Name
EntityRegistrantName
Elite Performance Holding Corp.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-5034226
dei Entity Address Address Line1
EntityAddressAddressLine1
3301 NE 1st Ave Suite M704
dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33137
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
426-2958
dei Entity Current Reporting Status
EntityCurrentReportingStatus
No
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
No
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
108991270 shares
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
30802 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
39852 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
30854 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32999 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
38484 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
89794 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
101400 usd
CY2024Q2 us-gaap Assets
Assets
162645 usd
CY2023Q4 us-gaap Assets
Assets
170738 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
879943 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
20022 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19064 usd
CY2023Q4 elite Advance From Customer
AdvanceFromCustomer
215000 usd
CY2024Q2 us-gaap Long Term Loans Payable
LongTermLoansPayable
95485 usd
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130397550 shares
CY2023Q4 elite Shares To Be Issued
SharesToBeIssued
50000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
6452938 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
5759788 usd
CY2024Q2 us-gaap Revenues
Revenues
611 usd
CY2023Q2 us-gaap Revenues
Revenues
16800 usd
us-gaap Revenues
Revenues
681 usd
us-gaap Revenues
Revenues
26708 usd
CY2024Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5560 usd
CY2023Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
14951 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
5560 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
30209 usd
CY2024Q2 us-gaap Gross Profit
GrossProfit
-4949 usd
CY2023Q2 us-gaap Gross Profit
GrossProfit
1849 usd
us-gaap Gross Profit
GrossProfit
-4879 usd
us-gaap Gross Profit
GrossProfit
-3501 usd
CY2024Q2 us-gaap Legal Fees
LegalFees
51084 usd
CY2023Q2 us-gaap Legal Fees
LegalFees
73918 usd
us-gaap Legal Fees
LegalFees
111501 usd
us-gaap Legal Fees
LegalFees
140641 usd
CY2024Q2 us-gaap Advertising Expense
AdvertisingExpense
5467 usd
CY2023Q2 us-gaap Advertising Expense
AdvertisingExpense
17557 usd
us-gaap Advertising Expense
AdvertisingExpense
8497 usd
us-gaap Advertising Expense
AdvertisingExpense
42211 usd
CY2024Q2 elite Consulting Expense
ConsultingExpense
-11983 usd
CY2023Q2 elite Consulting Expense
ConsultingExpense
114860 usd
elite Consulting Expense
ConsultingExpense
294417 usd
elite Consulting Expense
ConsultingExpense
231824 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
137493 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
132976 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
222710 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
246014 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
182061 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
339311 usd
us-gaap Operating Expenses
OperatingExpenses
637125 usd
us-gaap Operating Expenses
OperatingExpenses
660690 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-187010 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-337462 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-642004 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-664191 usd
CY2024Q2 us-gaap Other Income
OtherIncome
800 usd
CY2023Q2 us-gaap Other Income
OtherIncome
0 usd
us-gaap Other Income
OtherIncome
2245 usd
us-gaap Other Income
OtherIncome
0 usd
CY2024Q2 us-gaap Interest Expense
InterestExpense
47893 usd
CY2023Q2 us-gaap Interest Expense
InterestExpense
35639 usd
us-gaap Interest Expense
InterestExpense
91872 usd
us-gaap Interest Expense
InterestExpense
72869 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-47893 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35639 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-89627 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-72869 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-235012 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-373101 usd
us-gaap Net Income Loss
NetIncomeLoss
-731631 usd
us-gaap Net Income Loss
NetIncomeLoss
-737060 usd
CY2024Q2 elite Earnings Per Share Basic And Diluted Net Loss Per Common Share
EarningsPerShareBasicAndDilutedNetLossPerCommonShare
-0.00
CY2023Q2 elite Earnings Per Share Basic And Diluted Net Loss Per Common Share
EarningsPerShareBasicAndDilutedNetLossPerCommonShare
-0.00
elite Earnings Per Share Basic And Diluted Net Loss Per Common Share
EarningsPerShareBasicAndDilutedNetLossPerCommonShare
-0.01
elite Earnings Per Share Basic And Diluted Net Loss Per Common Share
EarningsPerShareBasicAndDilutedNetLossPerCommonShare
-0.01
CY2024Q2 elite Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
107622545 shares
CY2023Q2 elite Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
128959322 shares
elite Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
115175762 shares
elite Weighted Average Number Of Common Share Outstanding Basic And Diluted
WeightedAverageNumberOfCommonShareOutstandingBasicAndDiluted
128608924 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-2966360 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
86000 usd
CY2024Q1 elite Retirement Of Founder Shares Amount
RetirementOfFounderSharesAmount
0 usd
CY2024Q1 elite Warrants Issued For Services
WarrantsIssuedForServices
77623 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
35000 usd
CY2024Q1 elite Shares Issued As Debt Issuance Cost Amount
SharesIssuedAsDebtIssuanceCostAmount
5000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-496619 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-3259356 usd
CY2024Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
12000 usd
CY2024Q2 elite Retirement Of Founder Shares Amount
RetirementOfFounderSharesAmount
0 usd
CY2024Q2 elite Warrants Issued For Services
WarrantsIssuedForServices
15884 usd
CY2024Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
456786 usd
CY2024Q2 elite Shares Issued As Ap Amount
SharesIssuedAsApAmount
4500 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-235012 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-3005198 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-1805214 usd
CY2023Q1 elite Common Shares To Be Issued For Subscriptions Amount
CommonSharesToBeIssuedForSubscriptionsAmount
69000 usd
CY2023Q1 elite Common Shares Issued For Settlement Of Accounts Payable
CommonSharesIssuedForSettlementOfAccountsPayable
0 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
16000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-363959 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-2084173 usd
CY2023Q2 elite Reg D Subscriptions Amount
RegDSubscriptionsAmount
13000 usd
CY2023Q2 elite Common Shares To Be Issued For Subscriptions Shares
CommonSharesToBeIssuedForSubscriptionsShares
-9000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60000 usd
CY2023Q2 elite Shares To Be Issued For Services Shares
SharesToBeIssuedForServicesShares
-10000 shares
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
35000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-373101 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-2368274 usd
elite Profit And Loss
ProfitAndLoss
731631 usd
elite Profit And Loss
ProfitAndLoss
737060 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
17496 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
98000 usd
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
66000 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
93507 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
5041 usd
us-gaap Inventory Write Down
InventoryWriteDown
0 usd
us-gaap Depreciation
Depreciation
5485 usd
us-gaap Depreciation
Depreciation
5455 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-24194 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-27277 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
14069 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1295 usd
us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
-11606 usd
us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
-12108 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
64829 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
68625 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
117491 usd
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
141924 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-349731 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-372686 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
357000 usd
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
285000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
98500 usd
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
20000 usd
us-gaap Proceeds From Repayments Of Bank Overdrafts
ProceedsFromRepaymentsOfBankOverdrafts
0 usd
us-gaap Proceeds From Repayments Of Bank Overdrafts
ProceedsFromRepaymentsOfBankOverdrafts
0 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
9299 usd
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
6934 usd
elite Proceeds From Advances
ProceedsFromAdvances
22000 usd
elite Proceeds From Advances
ProceedsFromAdvances
50000 usd
elite Proceeds From Sale Of Common Stock And Shares To Be Issued
ProceedsFromSaleOfCommonStockAndSharesToBeIssued
0 usd
elite Proceeds From Sale Of Common Stock And Shares To Be Issued
ProceedsFromSaleOfCommonStockAndSharesToBeIssued
73000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
349701 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
432653 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-30 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
59967 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8993 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68960 usd
us-gaap Interest Paid Net
InterestPaidNet
4459 usd
us-gaap Interest Paid Net
InterestPaidNet
5406 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
491786 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
35000 usd
elite Gain On Related Party Accounts Payable Conversion
GainOnRelatedPartyAccountsPayableConversion
2700 usd
elite Gain On Related Party Accounts Payable Conversion
GainOnRelatedPartyAccountsPayableConversion
0 usd
elite Shares Issued As Debt Issuance Cost
SharesIssuedAsDebtIssuanceCost
5000 usd
elite Shares Issued As Debt Issuance Cost
SharesIssuedAsDebtIssuanceCost
0 usd
CY2024Q2 elite Accumulated Deficit
AccumulatedDeficit
-9525790 usd
CY2024Q2 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 usd
CY2024Q2 us-gaap Accounts Receivable Net
AccountsReceivableNet
0 usd
CY2024Q2 us-gaap Allowance For Doubtful Accounts Premiums And Other Receivables
AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables
0 usd
us-gaap Inventory Write Down
InventoryWriteDown
5041 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
25761 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
30802 usd
CY2024Q2 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
14069 usd
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
0 usd
CY2024Q2 us-gaap Convertible Debt
ConvertibleDebt
1124489 usd
CY2024Q2 us-gaap Interest Payable Current
InterestPayableCurrent
218968 usd
CY2024Q2 elite Common Stock Convertible Shares Issuable
CommonStockConvertibleSharesIssuable
21043805 shares
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
545250 usd
CY2023Q4 us-gaap Interest Payable Current
InterestPayableCurrent
259971 usd
CY2023Q4 elite Common Stock Convertible Shares Issuable
CommonStockConvertibleSharesIssuable
16104420 shares
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
0 usd
us-gaap Revenues
Revenues
681 usd
us-gaap Revenues
Revenues
26708 usd
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
89794 usd
CY2024Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
86695 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11719 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12108 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
4459 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
5406 usd
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
55000 usd
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
22001 usd
CY2024Q2 elite Property Plant And Equipments Net
PropertyPlantAndEquipmentsNet
32999 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
5485 usd
us-gaap Depreciation Nonproduction
DepreciationNonproduction
5515 usd
elite Property Plant And Equipment Estimated Useful Life
PropertyPlantAndEquipmentEstimatedUsefulLife
P5Y
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
465000000 shares
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
130397550 shares
CY2024Q2 us-gaap Common Stock Other Shares Outstanding
CommonStockOtherSharesOutstanding
109001270 shares
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0454 pure
us-gaap Debt Instrument Term
DebtInstrumentTerm
P4Y9M3D
elite Volatility
Volatility
2.36 pure
elite Commons Sockand Commons Sock Warrants Table Textblock
CommonsSockandCommonsSockWarrantsTableTextblock
<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Number </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>of</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Average</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at December 31, 2022</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired or cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">—</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at December 31, 2023</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">960,000</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercised</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Expired or cancelled</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Outstanding at June 30, 2024</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">960,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">2.00</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
CY2023 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0
elite Share Based Compensation Arrangement By Share Based Payment Award Options Issued Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedNumber
960000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
960000 shares
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
35000000 shares
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
10000000 shares
CY2017Q4 elite Preferred Stock Designated Value
PreferredStockDesignatedValue
1000 usd
CY2024Q2 elite Balances Of Advances
BalancesOfAdvances
12000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
820250 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
545250 usd
elite Proceeds From Convertibles Debt
ProceedsFromConvertiblesDebt
355000 usd
CY2023 elite Proceeds From Convertibles Debt
ProceedsFromConvertiblesDebt
330000 usd
elite Conversion Of Advances And Accrued Interest To Convertible Debt Instrument
ConversionOfAdvancesAndAccruedInterestToConvertibleDebtInstrument
420489 usd
CY2023 elite Conversion Of Advances And Accrued Interest To Convertible Debt Instrument
ConversionOfAdvancesAndAccruedInterestToConvertibleDebtInstrument
0 usd
elite Conversion Of Stock Amount Converted One
ConversionOfStockAmountConvertedOne
-471250 usd
CY2023 elite Conversion Of Stock Amount Converted One
ConversionOfStockAmountConvertedOne
-55000 usd
CY2024Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1124489 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
820250 usd
CY2024Q2 us-gaap Inventory Write Down
InventoryWriteDown
5041 usd
CY2024Q2 us-gaap Inventory Net
InventoryNet
25761 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
30802 usd
CY2024Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
25761 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
30802 usd

Files In Submission

Name View Source Status
0001477932-24-004946-index-headers.html Edgar Link pending
0001477932-24-004946-index.html Edgar Link pending
0001477932-24-004946.txt Edgar Link pending
0001477932-24-004946-xbrl.zip Edgar Link pending
elite-20240630.xsd Edgar Link pending
elite_10q.htm Edgar Link pending
elite_10qimg2.jpg Edgar Link pending
elite-20240630_def.xml Edgar Link unprocessable
elite-20240630_pre.xml Edgar Link unprocessable
elite_10q_htm.xml Edgar Link completed
elite_ex311.htm Edgar Link pending
elite_ex312.htm Edgar Link pending
elite_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
elite-20240630_cal.xml Edgar Link unprocessable
elite-20240630_lab.xml Edgar Link unprocessable